Downstream Manufacturing

INSIGHTS ON DOWNSTREAM MANUFACTURING

Achieving High Cell Purity With The CTS DynaCellect Magnetic Separation System
Learn how closed-system automation, combined with expert technical guidance and protocol optimization, turned a persistent manufacturing bottleneck into a reliable, scalable process.
Anticoagulant Selection Influences T Cell Purity And Yield In Whole Blood Isolation
Lithium heparin reduces T cell purity to below 50% and spikes CD15+ contamination in whole blood workflows. See which anticoagulants consistently deliver above 90% CD3+ purity.
3 Innovations For Reducing Risk In Continuous Downstream Bioprocessing
Batch-to-continuous transitions in downstream bioprocessing carry real risks. Here's how advanced analytics, smarter buffer strategies, and single-use systems are changing that calculus.
Aligning Upstream And Downstream Development (Part 1)
In this episode of “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development.

How To Select The Right Platform For Your Vaccine Production Process
4/16/2026

Evaluate surface treatments, scalability, and contamination risks to select the right adherent platform. Testing early ensures a seamless transition from benchtop to production.
Why Flexible, Tailored CDMO Support Is A Non-Negotiable In Sterile Fill-Finish
4/13/2026

Modern injectable programs require adaptable manufacturing strategies. Learn how flexibility, technical depth, and collaboration reduce complexity, manage change, and protect long‑term supply.
Optimize Time, Space and Cost With Inline Buffer Formulation And System
4/7/2026

Discover how integrating inline buffer formulation with chromatography reduces buffer waste by 50% and delivers a 710% ROI, transforming downstream efficiency and sustainability.
Evaluation Of TFF Operating Control Strategies And Scalability
4/2/2026

Gain insight into a comparison of TMP and permeate control strategies for viral vector TFF, highlighting impacts on flux, processing time, impurity removal, and scale-up predictability across development.
The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time
4/1/2026

See how controlled ice nucleation shortens lyophilization cycles, supports higher drying temperatures, and reduces complexity for amorphous and mixed formulations without sacrificing quality.

Advancing Cell Therapy With The CTS DynaCellect Magnetic Separation System

Closed, automated T cell isolation with greater than 85% efficiency and greater than 96% purity is now achievable in 70 to 100 minutes, with cGMP-ready scalability from research to clinical manufacturing.
Cell Therapy: T Cell Isolation From Whole Blood

Whole blood offers a faster, lower-cost starting material for T cell isolation and CTS Detachable Dynabeads CD4/CD8 with the DynaCellect System make it a viable, cGMP-aligned option without preprocessing.
Cell Therapy Selection Guide: Connected From Activation To Expansion

Active bead release gives manufacturers precise control over T cell isolation timing, phenotype preservation, and workflow efficiency, eliminating multi-day passive dissociation delays.
Integrated T Cell Activation: Soluble DynActivator CD3/CD28 Prototype

Bead-free T cell activation is now achievable with a soluble, GMP-compliant format that supports up to 1.5 billion cells per vial, decouples activation from isolation, and removes with a simple cell wash.
An Integrated, Verified PFS System For Vaccines

A pre-verified delivery platform eliminates redundant testing, simplifies regulatory submissions, and optimizes inventory management, allowing teams to focus on drug-specific performance.